Transgenic mouse studies reveal substantial roles for opioid receptors in the rewarding effects of several classes of addictive drugs

Current Psychiatry Reviews

Volumn 2, Issue 1, 2006, Pages 27-37

  Hall, F Scott ^a   Uhl, George R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Combinatorial knockouts; Conditioned place preference (CPP); DOR agonists; Hyperalgesia; Immunosuppressive; Molecular genetic; Morris water maze

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; COCAINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DRONABINOL; KAPPA OPIATE RECEPTOR; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; OPIATE RECEPTOR; PREPRODYNORPHIN; PREPROENKEPHALIN; SEROTONIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

ALCOHOLISM; ANIMAL MODEL; COCAINE DEPENDENCE; CONDITIONED REFLEX; DRUG DEPENDENCE; GENE DELETION; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INSTRUMENTAL CONDITIONING; KNOCKOUT MOUSE; LOCOMOTION; MORPHINE ADDICTION; MOUSE; NONHUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; REWARD; SOCIAL ISOLATION; TOBACCO DEPENDENCE; TRANSGENIC MOUSE; WITHDRAWAL SYNDROME;

EID: 33745823142     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340006775101526     Document Type: Review

References (112)

1. Minami M, Toya T, Katao Y, et al. Cloning and expression of a cDNA for the rat kappa-opioid receptor. FEBS Lett 1993; 329: 291-5.
2. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52.
3. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 1994; 338: 217-22.
4. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-52.
5. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819-23.
6. Sora I, Takahashi N, Funada M, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94: 1544-9.
7. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 1998; 54: 321-6.
8. Hall FS, Li XF, Goeb M, et al. Congenic C57BL/6 mu opiate receptor (MOR) knockout mice: baseline and opiate effects. Genes Brain Behav 2003; 2: 114-21.
9. Mansikka H, Zhao C, Sheth RN, Sora I, Uhl G, Raja SN. Nerve injury induces a tonic bilateral mu-opioid receptor-mediated inhibitory effect on mechanical allodynia in mice. Anesthesiology 2004; 100: 912-21.
10. Roy S, Barke RA, Loh HH. MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res 1998; 61: 190-4.
11. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 2002; 71: 782-90.
12. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. Morphine modulates lymph node-derived T lymphocyte function: role of caspase-3,-8, and nitric oxide. J Leukoc Biol 2001; 70: 527-36.
13. Roy S, Liu HC, Loh HH. mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit. Brain Res Mol Brain Res 1998; 56: 281-3.
14. Sarton E, Teppema L, Nieuwenhuijs D, Matthes HW, Kieffer B, Dahan A. Opioid effect on breathing frequency and thermogenesis in mice lacking exon 2 of the mu-opioid receptor gene. Adv Exp Med Biol 2001; 499: 399-404.
15. Romberg R, Sarton E, Teppema L, Matthes HW, Kieffer BL, Dahan A. Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br J Anaesth 2003; 91: 862-70.
16. Dahan A, Sarton E, Teppema L, et al. Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice. Anesthesiology 2001; 94: 824-32.
17. Becker A, Grecksch G, Brodemann R, el al. Morphine self-administration in mu-opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 584-9.
18. Tian M, Broxmeyer HE, Fan Y, et al. Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J Exp Med 1997; 185: 1517-22.
19. Sora I, Elmer G, Funada M, et al. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 2001; 25: 41-54.
20. Kitanaka N, Sora I, Kinsey S, Zeng Z, Uhl GR. No heroin or morphine 6beta-glucuronide analgesia in mu-opioid receptor knockout mice. Eur J Pharmacol 1998; 355: R1-3.
21. Contarino A, Picetti R, Matthes HW, Koob GF, Kieffer BL, Gold LH. Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice. Eur J Pharmacol 2002; 446: 103-9.
22. Skoubis PD, Matthes HW, Walwyn WM, Kieffer BL, Maidment NT. Naloxone fails to produce conditioned place aversion in muopioid receptor knock-out mice. Neuroscience 2001; 106: 757-63.
23. Lutfy K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003; 23: 10331-7.
24. Ide S, Minami M, Satoh M, Uhl GF, Sora I, Ikeda K. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 2004; 29: 1656-63.
25. Kitchen I, Slowe SJ, Matthes HWD, Kieffer B. Quantitative autoradiographic mapping of μ, δ- and κ-opioid receptors in knockout mice lacking the μ-opioid receptor gene. Brain Res 1997; 778: 73-88.
26. De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neurosci 2002; 22: 3321-5.
27. Shippenberg TS, Elmer GI. The neurobiology of opiate reinforcement. Crit Rev Neurobiol 1998; 12: 267-303.
28. Stevens KE, Mickley GA, McDermott LJ. Brain areas involved in production of morphine-induced locomotor hyperactivity of the C57B1/6J mouse. Pharmacol Biochem Behav 1986; 24: 1739-47.
29. Simone DA, Bodnar RJ, Portzline T, Pasternak GW. Antagonism of morphine analgesia by intracerebroventricular naloxonazine. Pharmacol Biochem Behav 1986; 24: 1721-7.
30. Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 1978; 276: 186-8.
31. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA 1993; 90: 5391-3.
32. Matthes HW, Smadja C, Valverde O, et al. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu- receptor. J Neurosci 1998; 18: 7285-95.
33. Martin M, Matifas A, Maldonado R, Kieffer BL. Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. Eur J Neurosci 2003; 17: 701-8.
34. Narita M, Mizoguchi H, Sora I, Uhl GR, Tseng LF. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice. Br J Pharmacol 1999; 126: 451-6.
35. Mizoguchi H, Narita M, Oji DE, et al. The mu-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in mu-opioid receptor knockout mice. Neuroscience 1999; 94: 203-7.
36. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 1999; 96: 7752-5.
37. Berrendero F, Kieffer BL, Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 2002; 22: 10935-40.
38. Sora I, Funada M, Uhl GR. The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin- induced analgesia. Eur J Pharmacol 1997; 324: R1-2.
39. Fuchs PN, Roza C, Sora I, Uhl G, Raja SN. Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice. Brain Res 1999; 821: 480-6.
40. Moles A, Kieffer BL, D'Amato FR. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 2004; 304: 1983-6.
41. Yoo JH, Lee SY, Loh HH, Ho IK, Jang CG. Altered emotional behaviors and the expression of 5-HT1A and M1 muscarinic receptors in micro-opioid receptor knockout mice. Synapse 2004; 54: 72-82.
42. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000; 25: 195-200.
43. Belknap JK, Crabbe JC. Chromosome mapping of gene loci affecting morphine and amphetamine responses in BXD recombinant inbred mice. Ann N Y Acad Sci 1992; 654: 311-23.
44. Belknap JK, Mogil JS, Helms ML, et al. Localization to chromosome 10 of a locus influencing morphine analgesia in crosses derived from C57BL/6 and DBA/2 strains. Life Sci 1995; 57: PL117-24.
45. Berrettini WM, Ferraro TN, Alexander RC, Buchberg AM, Vogel WH. Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994; 7: 54-8.
46. Belknap JK, Lame M, Danielson PW. Inbred strain differences in morphine-induced analgesia with the hot plate assay: a reassessment. Behav Genet 1990; 20: 333-8.
47. Belknap JK, Noordewier B, Lame M. Genetic dissociation of multiple morphine effects among C57BL/6J, DBA/2J and C3H/HeJ inbred mouse strains. Physiol Behav 1989; 46: 69-74.
48. Belknap JK, Crabbe JC, Riggan J, O'Toole LA. Voluntary consumption of morphine in 15 inbred mouse strains. Psychopharmacology (Berl) 1993; 112: 352-8.
49. Belknap JK, Riggan J, Cross S, Young ER, Gallaher EJ, Crabbe JC. Genetic determinants of morphine activity and thermal responses in 15 inbred mouse strains. Pharmacol Biochem Behav 1998; 59: 353-60.
50. Semenova S, Kuzmin A, Zvartau E. Strain differences in the analgesic and reinforcing action of morphine in mice. Pharmacol Biochem Behav 1995; 50:17-21.
51. Baran A, Shuster L, Eleftheriou BE, Bailey DW. Opiate receptors in mice: genetic differences. Life Sci 1975; 17: 633-40.
52. Elmer GI, Pieper JO, Goldberg SR, George FR. Opioid operant self-administration, analgesia, stimulation and respiratory depression in mu-deficient mice. Psychopharmacology (Berl) 1995; 117: 23-31.
53. Moskowitz AS, Terman GW, Carter KR, Morgan MJ, Liebeskind JC. Analgesic, locomotor and lethal effects of morphine in the mouse: strain comparisons. Brain Res 1985; 361: 46-51.
54. Mogil JS, Kest B, Sadowski B, Belknap JK. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 1996; 276: 532-44.
55. Hummel M, Ansonoff MA, Pintar JE, Unterwald EM. Genetic and pharmacological manipulation of mu opioid receptors in mice reveals a differential effect on behavioral sensitization to cocaine. Neuroscience 2004; 125: 211-20.
56. Altman J, Everitt BJ, Glautier S, et al. The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology (Berl) 1996; 125: 285-345.
57. White NM, McDonald RJ. Multiple parallel memory systems in the brain of the rat. Neurobiol Learn Mem 2002; 77: 125-84.
58. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 2002; 161: 1-16.
59. Hutcheson DM, Matthes HW, Valjent E, et al. Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. Eur J Neurosci 2001; 13: 153-61.
60. Hosohata Y, Vanderah TW, Burkey TH, et al. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice. Eur J Pharmacol 2000; 388: 241-8.
61. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J Neurosci 2002; 22: 1146-1154.
62. Hall FS, Sora I, Uhl GR. Ethanol consumption and reward are decreased in μ-opiate receptor knockout mice. Psychopharmacology (Berl) 2001; 154: 43-9.
63. Becker A, Grecksch G, Kraus J, Loh HH, Schroeder H, Hollt V. Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 296-302.
64. Hall FS, Goeb M, Li XF, Sora I, Uhl GR. μ-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res Mol Brain Res 2004; 121: 123-30.
65. Robledo P, Mendizabal V, Ortuno J, de la Torre R, Kieffer BL, Maldonado R. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur J Neurosci 2004; 20: 853-8.
66. Hall FS. Social deprivation of neonatal, adolescent, and adult rats has distinct neurochemical and behavioral consequences. Crit Rev Neurobiol 1998; 12:129-62.
67. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003; 27: 199-217.
68. Roberts AJ, McDonald JS, Heyser CJ, et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293: 1002-8.
69. Mathon DS, Lesscher HM, Gerrits MA, et al. Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice. Neuroscience 2005; 130: 359-67.
70. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987; 94: 469-92.
71. Robinson TE, Browman KE, Crombag HS, Badiani A. Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 1998; 22: 347-54.
72. Yoo JH, Lee SY, Loh HH, Ho IK, Jang CG. Loss of nicotine-induced behavioral sensitization in micro-opioid receptor knockout mice. Synapse 2004; 51: 219-23.
73. Chefer VI, Kieffer BL, Shippenberg TS. Contrasting effects of mu opioid receptor and delta opioid receptor deletion upon the behavioral and neurochemical effects of cocaine. Neuroscience 2004; 127: 497-503.
74. Yoo J-H, Yang E-M, Lee S-Y, Loh HH, Ho IK, Jang C-G. Differential effects of morphine and cocaine on locomotor activity and sensitization in μ-opioid receptor knockout mice. Neurosci Lett 2003; 344(37-40).
75. Castane A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 2003; 17: 155-9.
76. Slowe SJ, Clarke S, Lena I, et al. Autoradiographic mapping of the opioid receptor-like 1 (ORL1) receptor in the brains of mu-, delta-or kappa-opioid receptor knockout mice. Neuroscience 2001; 106: 469-80.
77. Zhou Y, Spangler R, Schlussman SD, et al. Effects of acute "binge" cocaine on preprodynorphin, preproenkephalin, proopiomelanocortin, and corticotropin-releasing hormone receptor mRNA levels in the striatum and hypothalamic-pituitary-adrenal axis of mu-opioid receptor knockout mice. Synapse 2002; 45: 220-9.
78. Sora I, Li XF, Funada M, Kinsey S, Uhl GR. Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488. Eur J Pharmacol 1999; 366: R3-5.
79. Qiu C, Sora I, Ren K, Uhl G, Dubner R. Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. Eur J Pharmacol 2000; 387: 163-9.
80. Park Y, Ma T, Tanaka S, el al. Comparison of G-protein activation in the brain by mu-, delta-, and kappa-opioid receptor agonists in mu-opioid receptor knockout mice. Brain Res Bull 2000; 52: 297-302.
81. Morinville A, Cahill CM, Esdaile MJ, et al. Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci 2003; 23: 4888-98.
82. Morinville A, Cahill CM, Kieffer B, Collier B, Beaudet A. Mu-opioid receptor knockout prevents changes in delta-opioid receptor trafficking induced by chronic inflammatory pain. Pain 2004; 109: 266-73.
83. Park Y, Ho IK, Fan L-W, Loh HH, Ko KH. Region specific incrase of dopamine receptor D1/D2 mRNA expression in the brain of μ-opioid receptor knockout mice. Brain Res 2001; 894: 311-315.
84. Tien LT, Park Y, Fan LW, Ma T, Loh HH, Ho IK. Increased dopamine D2 receptor binding and enhanced apomorphine-induced locomotor activity in mu-opioid receptor knockout mice. Brain Res Bull 2003; 61: 109-15.
85. Matthies H, Schroeder H, Becker A, Loh H, Hollt V, Krug M. Lack of expression of long-term potentiation in the dentate gyrus but not in the CA1 region of the hippocampus of mu-opioid receptor-deficient mice. Neuropharmacology 2000; 39: 952-60.
86. Chefer VI, Kieffer BL, Shippenberg TS. Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice. Eur J Neurosci 2003; 18: 1915-22.
87. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-91.
88. Berrendero F, Mendizabal V, Murtra P, Kieffer BL, Maldonado R. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS, binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur J Neurosci 2003; 18: 2197-202.
89. Jang CG, Lee SY, Loh HH, Ho IK. Lack of mu-opioid receptor leads to an increase in the NMDA receptor subunit mRNA expression and NMDA-induced convulsion. Brain Res Mol Brain Res 2001; 94: 105-11.
90. Park Y, Jang CG, Yang KH, Loh HH, Ma T, Ho IK. Regional specific increases of [3H]AMPA binding and mRNA expression of AMPA receptors in the brain of mu-opioid receptor knockout mice. Brain Res Mol Brain Res 2003; 113: 116-23.
91. Grecksch G, Becker A, Schroeder H, Kraus J, Loh H, Hollt V. Accelerated kindling development in mu-opioid receptor deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 287-93.
92. Sarton E, Teppema LJ, Olievier C, el al. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001; 93: 1495-500, table of contents.
93. Jamot L, Matthes HW, Simonin F, Kieffer BL, Roder JC. Differential involvement of the mu and kappa opioid receptors in spatial learning. Genes Brain Behav 2003; 2: 80-92.
94. Jang CG, Lee SY, Yoo JH, et al. Impaired water maze learning performance in mu-opioid receptor knockout mice. Brain Res Mol Brain Res 2003; 117: 68-72.
95. Kas MJ, van den Bos R, Baars AM, et al. Mu-opioid receptor knockout mice show diminished food-anticipatory activity. Eur J Neurosci 2004; 20: 1624-32.
96. Roy S, Wang JH, Balasubramanian S, et al. Role of hypothalamic-pituitary axis in morphine-induced alteration in thymic cell distribution using mu-opioid receptor knockout mice. J Neuroimmunol 2001; 116: 147-55.
97. Liu IM, Chi TC, Shiao GC, Lin MT, Cheng JT. Loss of plasma glucose lowering response to cold stress in opioid mu-receptor knock-out diabetic mice. Neurosci Lett 2001; 307: 81-4.
98. Roberts AJ, Gold LH, Polis I, et al. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res 2001; 25: 1249-56.
99. Zhu Y, King MA, Schuller AG, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999; 24: 243-52.
100. Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 2002; 22: 10906-13.
101. Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, Traynor JR. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 2002; 303: 723-9.
102. Goody RJ, Oakley SM, Filliol D, Kieffer BL, Kitchen I. Quantitative autoradiographic mapping of opioid receptors in the brain of delta-opioid receptor gene knockout mice. Brain Res 2002; 945: 9-19.
103. Simonin F, Valverde O, Smadja C, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. Embo J 1998; 17: 886-97.
104. Xu M, Petraschka M, McLaughlin JP, et al. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci 2004; 24: 4576-84.
105. Sora I, Hall FS, Andrews AM, et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci USA 2001; 98: 5300-5.
106. Gaveriaux-Ruff C, Filliol D, Simonin F, Matthes HW, Kieffer BL. Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther 2001; 298: 1193-8.
107. Hough LB, Nalwalk JW, Chen Y, et al. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res 2000; 880: 102-8.
108. Simonin F, Slowe S, Becker JA, et al. Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol 2001; 414: 189-95.
109. Sora I, Wichems C, Takahashi N, et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998; 95: 7699-704.
110. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710-26.
111. Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004; 14: 209-16.
112. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict 2003; 12 Suppl 1:S53-68.